“…The overall structures of 161519 TriKE in our study and the one designed previously 20 were identical. However, the anti-CD16 and anti-CD19 antibody sequences 16 , 23 used in our study were different from the ones used previously 25 , 26 . In addition, our study used in vivo models to show that 161519 TriKE promoted the proliferation and survival of human NK cells and mediated stronger anti-tumor responses compared with that by 1619 BiKE.…”